SOURCE: BIOLASE Technology, Inc.

September 17, 2008 06:00 ET

BIOLASE Commences Shipments of New Waterlase® C100 All-Tissue Dental Laser System

IRVINE, CA--(Marketwire - September 17, 2008) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has begun shipping its new Waterlase® C100 hard and soft tissue laser to customers worldwide.

Designed for restorative and general dentistry, the Waterlase C100 can be used for a range of clinical procedures including cavity preparation, treating various periodontal conditions as well as soft tissue procedures that allow more patient comfort compared to conventional instrumentation. Introduced as part of the Company's new and expanded product strategy, Waterlase C100 is priced to appeal to a broader cross section of the dental market.

BIOLASE Chief Executive Officer Jake St. Philip said, "We are working hard to establish an environment of execution at BIOLASE, and it is gratifying to see the product development and launch efforts surrounding the C100 move forward as scheduled. This product rounds out our hard-tissue laser offering and we expect it to be complimentary to our flagship Waterlase MD device."

The Waterlase C100 all-tissue laser combines industry-leading Waterlase YSGG technology with excellent reliability, clinician control, operating efficiency, and flexibility in tip and accessory selection. While it offers a narrower scope of applications than Waterlase MD, it provides for an advanced level of clinical results and patient comfort in a wide range of hard and soft tissue procedures.

The addition of the Waterlase C100 to the product family complements the market leading Waterlase MD all-tissue laser and the highly successful ezlase™ diode soft tissue laser and now gives BIOLASE a full range of Waterlase Dentistry solutions to meet the laser needs of almost every practice regardless of age, size or specialization.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (, the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, contact:
    David M. Mulder
    Chief Financial Officer of BIOLASE Technology, Inc.

    Jill Bertotti
    Allen & Caron